mebeverine
Small moleculeexperimental
Mebeverine is a drug used to alleviate some of the symptoms of irritable bowel syndrome. It works by relaxing the muscles in and around the gut. — Wikipedia
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
2
Earliest trial started Apr 1, 2010 (NCT00934973)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Muscarinic acetylcholine receptorINHIBITOR
Muscarinic acetylcholine receptor inhibitor
- Muscarinic acetylcholine receptor M3 (CHRM3) ↗
- Muscarinic acetylcholine receptor M4 (CHRM4) ↗
- Muscarinic acetylcholine receptor M1 (CHRM1) ↗
- Muscarinic acetylcholine receptor M5 (CHRM5) ↗
- Muscarinic acetylcholine receptor M2 (CHRM2) ↗
- Muscarinic acetylcholine receptor M2
- Muscarinic acetylcholine receptor M1
- Muscarinic acetylcholine receptor M4
- Muscarinic acetylcholine receptor M5
- Muscarinic acetylcholine receptor M3
- Muscarinic acetylcholine receptors; M2 & M3
- Muscarinic acetylcholine receptors; M1 & M2
- Muscarinic acetylcholine receptor M1/M5 chimeric protein
- Muscarinic acetylcholine receptor M1 and M3
- Muscarinic acetylcholine receptor M2 and M4
- Muscarinic acetylcholine receptor M2 and M5
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1- Mol. weight
- 429.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL282121 ↗
- WikipediaMebeverine ↗
- ChEMBLCHEMBL1446650 ↗
Also known as
- 4-(ethyl-(4-methoxy-alpha-methylphenethyl)aminobutyl) veratrate
- csag 144
- duspatalin
- mebeverine
- mebeverine
- mebeverine
- mebeverine
- mebeverine
- mebeverine
- mebeverine
- mebeverine
- mebeverine hcl
- mebeverine hcl
- mebeverine hcl
- mebeverine hydrochloride
- mebeverine hydrochloride
- mebeverine hydrochloride
- mebeverine hydrochloride
- spasmotalin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05175131 | Phase 3 | Nov 27, 2020 | Abbott |
| NCT04217733 | Phase 3 | Nov 1, 2019 | Tanta University |
| NCT04635566 | N/A | Mar 1, 2019 | Mansoura University |
| NCT03147599 | Phase 4 | May 15, 2017 | Mansoura University |
| NCT00934973 | Phase 4 | Apr 1, 2010 | Moorgreen Hospital, Southampton, National Institute for Health Research, United Kingdom, University of Southampton |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mansoura University | Academic/Hospital | 2 | 2 | 2 | 2017 |
| Abbott | For profit | 1 | 1 | 1 | 2020 |
| Moorgreen Hospital, Southampton | Academic/Hospital | 1 | 0 | 1 | 2010 |
| National Institute for Health Research, United Kingdom | Government | 1 | 0 | 1 | 2010 |
| Tanta University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Southampton | Academic/Hospital | 1 | 1 | 1 | 2010 |
6 organizations
Page 1 / 1